Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline
1. Jazz Pharmaceuticals to acquire Chimerix for $8.55 per share in cash. 2. Transaction expected to close in Q2 2025, valued at $935 million. 3. Chimerix's lead asset dordaviprone targets rare brain tumors in children. 4. FDA accepted New Drug Application for dordaviprone, Priority Review granted. 5. CMRX's stock surged 69.7% following acquisition news.